

MEDIMMUNE INC /DE  
Form 8-K  
April 12, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D. C. 20549

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)

April 12, 2007

**MedImmune, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation  
or organization)

**0-19131**  
(Commission File No.)

**52-1555759**  
(I.R.S. Employer Identification No.)

**One MedImmune Way, Gaithersburg, MD 20878**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code **(301) 398-0000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01** Other Events.

On April 12, 2007, MedImmune, Inc. (the Company) issued a press release announcing that it was exploring possible strategic alternatives. A copy of the Company's press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 9.01.** Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release by MedImmune, Inc., dated April 12, 2007.

2

---

**SIGNATURE**

**Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.**

**MedImmune, Inc.**

Date: April 12, 2007

By:

/s/ William C. Bertrand, Jr. Esq.  
William C. Bertrand Jr., Esq.  
Senior Vice President, General Counsel &  
Corporate Secretary

3

---

**EXHIBIT INDEX**

Exhibit

No.	Description
99.1	Press Release by MedImmune, Inc., dated April 12, 2007.

4

---